South-East Asian Commercialization Agreement Secured
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Memphasys Ltd has announced an exclusive commercialization agreement with TMSC Viet Nam Medical Technology Company Limited for the Felix™ sperm separation system in Vietnam, marking its first commercial partnership in South-East Asia. This agreement represents a significant expansion of Memphasys' international distribution network into a rapidly growing IVF market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Memphasys
- ITL Orders 1000 Felix Cartridges Across MENA Markets
- Quarterly Activities/Appendix 4C Cash Flow Report
- Investor Presentation - April 2026
- MENA Orders Secured, Expanded & Operations Unaffected
- Appendix 4D - Half-year Financial Report - 31 December 2025
Later from Memphasys
- Memphasys Executes Supply Agreement with Monash IVF Group
- Successful $1.2M Placement and Convertible Note Extended
- UK Market Entry & Acceleration of Commercial Expansion
- Exclusive Thailand Commercialisation Agreement Secured
- European Commercial Roll-out continues with Poland Agreement
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys